LENSAR Reports Third Quarter Results to Nov. 10
Investors tracking robotic cataract surgery equipment will get LENSAR's next commercial performance data on November 10.
Updated on Nov. 3, 2026 in Public Companies
LENSAR, Inc. (Nasdaq: LNSR) will release its third quarter 2026 financial results before market open on November 10, 2026. The medical technology company, which makes robotic laser systems for cataract treatment, will also host a conference call and webcast that morning.
Why it matters
Quarterly results and the accompanying management commentary are the primary channel through which investors and operators in the medical device sector assess a company's commercial traction. For businesses tracking surgical equipment suppliers, the timing gives an early read on demand for advanced cataract procedure technology.
The third quarter 2026 release is scheduled for November 10, 2026, with the conference call starting at 8:30 am ET. No revenue, earnings, or prior-period comparison figures have been disclosed yet, so the results will need to be assessed against LENSAR's prior quarters once published.
The players
LENSAR, Inc.
A global medical technology company, traded on Nasdaq as LNSR, that develops advanced robotic laser systems for cataract surgery.
The details
LENSAR's ALLY Robotic Cataract Laser System is designed to perform the entire cataract procedure in a sterile operating room or in-office surgical suite. The system uses an extremely fast dual-modality laser and integrates AI into proprietary imaging and software, including the company's Streamline software, which is designed to guide surgeons toward better outcomes. Management will use the call to discuss results and recent operational highlights, and participants must register online in advance.
Timeline
November 3, 2026: LENSAR announces the date and call details for its third quarter results.
November 10, 2026: Third quarter 2026 results are released before market open.
November 10, 2026, 8:30 am ET: Conference call and webcast begin.
Market Landscape
LENSAR's results will be read against the broader market for robotic cataract surgery, where its ALLY system competes as a single-platform approach to the full procedure. The November release gives investors their next data point on whether that positioning is translating into commercial results.
Operators in medical device distribution and surgical equipment procurement should watch the November 10 release for signals on demand for advanced cataract technology. Those tracking supplier financial health can use the results to inform vendor-risk reviews once the figures are public.
The takeaway
The November 10 release is the next hard data point on LENSAR's commercial performance, so it is worth adding to a medical device sector watchlist. Readers who need to register for the 8:30 am ET call should do so in advance through the investor relations page.
What happens next
Third quarter 2026 results and the accompanying conference call are scheduled for November 10, 2026, with the call beginning at 8:30 am ET.
Further reading
For context on how companies like LENSAR report to investors, see the Public Companies section.
More information
Access the live webcast and archived materials through the LENSAR investor relations website.
